Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nabriva (NBRV) and Alimera (ALIM).
Nabriva (NBRV)
H.C. Wainwright analyst Ed Arce maintained a Hold rating on Nabriva today. The company’s shares closed last Wednesday at $0.67, close to its 52-week low of $0.49.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 19.8% and a 44.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.
Nabriva has an analyst consensus of Moderate Buy, with a price target consensus of $1.50.
See today’s analyst top recommended stocks >>
Alimera (ALIM)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Alimera, with a price target of $14.00. The company’s shares closed last Wednesday at $5.58.
According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.4% and a 44.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.
Currently, the analyst consensus on Alimera is a Moderate Buy with an average price target of $14.50, representing a 163.6% upside. In a report issued on July 7, B.Riley FBR also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
